PTX-061 / Pleco Therap, Hyloris Pharma - LARVOL DELTA

Pleco Therapeutics Announces Final Close of its Series A Financing Raising €17.3m to Progress its Novel Plecoid Product in Acute Myeloid Leukaemia to Regulatory Filing in USA and EU (PRNewswire) - "Pleco Therapeutics BV...announces the final close of its Series A financing, with total funds raised of €17.3 million. The funds will be used to complete development and commercialise the Company's novel lead Plecoid Product, PTX-061, to improve the effectiveness of chemotherapy in patients with Acute Myeloid Leukaemia (AML). In total, at final close, the round exceeds the Company's goal of €15 million. It provides sufficient funds to complete the development of PTX-061's regulatory dossier in AML and to be ready for submission to the FDA and EMA as early as 2024, and to accelerate preclinical work in other indications such as Small-Cell Lung Cancer (SCLC)."

European regulatory • Financing • IND • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

"Netherlands #biotech @PlecoTx raises €17m to take preclinical tumour microenvironment drug PTX-061 through to US and EU regulatory filings for acute myeloid #leukaemia (AML) https://t.co/rEeW4DIgYZ" (@pharmaphorum)

European regulatory • Preclinical • Tumor microenvironment • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology